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Abstract
Scintigraphic techniques have opened a new era of developments in the local-
ization of infectious and cancerous foci. Diseases area targeting mechanisms of 
radiopharmaceuticals encompasses visualization, characterization, and measure-
ment of physiological and biological functioning at targeted sites in addition to 
measure the area and density of the disease. The accumulation of a radiopharma-
ceutical at specific organ is based upon numerous processes such as enzymatic 
interactions, receptor binding site, transport of chemical species and elimination of 
damaged cells from circulation by a normal metabolic process. PET and SPECT are 
developing scanning techniques that provides effective diagnostic tool to identify 
pathophysiology of diseased cells. In this chapter, we are exploring and explaining 
different mechanisms of radiopharmaceutical localization for imaging and thera-
peutic processes. The knowledge of these mechanisms will help to develop target 
based new radiopharmaceuticals using variety of medically used radioisotopes 
either for imaging or therapy of diseased cells.
Keywords: radiopharmaceuticals, SPECT imaging, antibiotics, infections, cancer
1. Introduction
Dysfunction and disruption of healthy physiological and biochemical cycles 
lead to the formation of malignancies. As the treatment of many diseases involves 
biochemical reactions so it may provide a basis for diagnosis. Several radiophar-
maceuticals widely available that use to visualize the functioning and structure of 
body cells, tissues, and organs. These radiopharmaceuticals formulated for treating 
several malignancies, pain palliation due to bony metastases, joint diseases, and 
many other similar conditions. Nuclear medicine basically, a medical specialty 
comprises a carrier molecule and radiotracer that image the regional biochemistry 
of the body. The biochemical nature of carrier molecule and radiotracer; effects 
on organ uptake, retention, transportation and biodistribution towards targeted 
area. So, it’s essential to know about the biochemistry of radiopharmaceuticals for 
better understanding [1]. Nuclear pharmacists must understand how radiopharma-
ceuticals localize and initiate its work, aka action mechanism. This expertise was 
required to assess the substrate specific and non-specific nature of labeled drug, 
its pharmacokinetics and biodistribution because life matters. As the radiophar-
maceuticals provide us an opportunity for timely diagnostics using blood flow, 
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multi-molecular cell localization, bio-energies, tissue metabolism, physiological 
functioning of the organ, intercellular and intracellular communicative pathways 
[2]. Different radiopharmaceuticals are used to image different organs based on the 
functioning of the organ. For example, the labeled iodine would be ideal for imag-
ing thyroid malignancies, because inorganic iodine absorbed more in the thyroid. 
Similarly, radiolabeled phosphate widely used for the bone scan as it is observed 
that phosphate ions more accumulated in the bone. Hence one can use the same 
labeled atoms for organ imaging, which are more accumulated there.
A radiopharmaceuticals localization mechanism is specific to targeted organs 
depends on processes as varied as antigen–antibody reactions, physical particle 
trapping, receptor site binding, removal of deliberately damaged cells from circula-
tion, and transportation of a chemical species across a cell membrane and into the 
cell via a normally operational metabolic cycle. Chemically, radiochemistry plays 
a crucial role in producing these compounds and in conducting quality assurance 
procedures to ensure purity [1, 3].
Some other factors also important for the selection and action of radiopharma-
ceuticals like for diagnosis gamma emitters were preferably choose (beta emitter 
in case of therapeutic), energy threshold 100–250 Kev, high T/NT ratio last but not 
least teff must be moderately long.
Furthermore, insoluble radiopharmaceuticals such as 99mTc-MAA and 99mTc-SC 
are used to represent the lungs and liver/spleen, diagnostic tests, respectively. Since 
it is well known that these two organs extract particles from the bloodstream, selec-
tion based entirely on particle size instead to chemical composition.
The mechanisms explained are not specific to radiopharmaceuticals, but these 
may be appropriate for some instances to explain the localization mechanisms 
of nuclear medicines. Radiopharmaceuticals are not limited to a mechanism but 
requires a combination of more than one mechanism. Lastly, a comprehensive 
overview of radiopharmaceuticals characteristics, their mode of action and detailed 
examples are given.
2. Mechanism of localization
The success of the molecular imaging technique using radioisotope labeled 
molecules commonly termed as radiopharmaceuticals relies on the mechanism of 
localization at disease cells. In the following sections we are explaining different 
mechanisms of radiopharmaceutical localization undertaken either for imaging 
process or therapy of diseases.
2.1 Compartmental localization
Generally, the phenomenon in which the desired species are disseminated 
in a bounded space is named as compartmentalization or may also be termed as 
compartmental localization and basically this bounded space is called as a compart-
ment. Specifically, in radio pharmacy compartment-localization means to put a 
radiotracer in a bounded space and sustaining the tracer for time being enough 
to scan that bounded space. The bounded space contains fluids (either liquid or 
gas). The fluids of compartment move systematically in normal circumstances but 
the pathophysiological changes cause anomalies in the motion of compartmental 
fluids. These conditions if left unattended and untreated may become fatal. But the 
conventional diagnostic techniques fail to localize the exact location of abnormal-
ity, so, here radio pharmacy provides refuge and we can get exact pinpoint location 
along with treatment from molecular imaging.
3Localization Mechanisms of Radiopharmaceuticals
DOI: http://dx.doi.org/10.5772/intechopen.94099
The compartments in biological systems are: Vascular system (blood vessels), 
Airways of lungs, cerebrospinal fluid (CSF) space, Abdominal (peritoneal) cavity, 
Alimentary (digestive/GI) tract, urinary system, lymphatic vessels.
The compartmental localization could be in the form of:
a. Uniform distribution inside compartment
b. Non-uniform distribution within compartment
c. Outflow from compartment
d. Flow within the compartment
2.1.1 Uniform distribution inside compartment
Vascular system is the most typical example of uniform dispersion inside com-
partment. By utilizing the tracer dilution method blood volume could be analyzed 
quantitatively. A radiopharmaceutical named I-125 RISA (Radio-Iodinated Serum 
Albumin) diffuses uniformly in blood plasma, is employed to determine volume of 
plasma in blood.
• Cr-51 labeled RBCs is another radiotracer that is applied to evaluate the mass of 
red cells (volume of red cells in blood). This radiotracer distributes itself inside 
the blood’s cellular part uniformly.
• Another radiotracer technetium-99 m labeled RBCs homogenously diffuses in 
blood, is used to evaluate expulsion fraction of left ventricle and movement of 
left ventricular wall by using gated blood-pool scanning.
2.1.2 Non-uniform distribution within compartment
Radiopharmaceuticals are not distributed equally every time. In some conditions 
they exhibit non-uniform dispersion, therefore showing disordered physiological 
process (due to some disease or injury). The increased concentration of a radiophar-
maceutical in any organ or tissue corresponds to the disturbance in normal physi-
ological function of that organ or tissue (pathologic changes).
Examples:
• Hemangioma is a condition in which a bright-red bump having extra blood 
vessels appears on skin and is quite rubbery. Extra blood vessels mean extra 
blood in that region. So, technetium-99 m labeled RBCs shows amplified 
localization in this region due to escalated volume of blood.
• Hydronephrosis is the inflammation of a kidney triggered by the accu-
mulation of urine in kidney. This condition prevails when urine could not 
be drained out from kidney to bladder owing to some sort of obstruction 
or blockade. MAG3 and DTPA radiolabeled with 99mTc are used for its 
imaging. But, MAG3 has preference over DTPA due to its good output. 
Mercaptoacetyltriglycine (MAG3) is a peptide radiolabeled with 99mTc and 
it is released in kidney tubules. So, this increased volume of urine results in 
escalated amount of 99mTc-mertiatide (MAG3) or 99mTc-pentetate (DTPA) 
tracer in affected kidney.
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The decreased concentration of the radiotracer in a compartmental cavity is usu-
ally the outcome of block in the cavity as mentioned in following examples:
• Xenon-133 ventilation imaging of lungs is used to confirm the obstruction in 
airways of lungs. This radiotracer will not be present past the block in the case 
of complete obstruction. While in partial hindrance, Xenon-133 would not 
be present in affected region after preliminary breathing but with time thru 
equilibrium rebreathing the radiotracer travel through the areas of partial 
hindrance.
• The obstruction in cerebrospinal fluid space could be monitored by intrathe-
cal injecting 111Indium-pentetate (DTPA). After injection 111Indium-DTPA 
normally drifts up the spine and all over the brain. But in case of obstructing 
hydrocephalus, hindrance impedes the movement of 111In-DTPA [4].
2.1.3 Outflow from the compartment
An uncharacteristic escape of content from compartmental space occurs owing 
to some pathologic changes (disturbances in normal physiological function). Radio 
pharmacy has a good lot of tracers that can precisely sense and find the location of 
compartmental leakage.
2.1.3.1 Mechanism of technetium-99 m labeled RBCs
Technetium-99 m labeled RBCs are used to foresee the exact location of 
Gastrointestinal bleeding. Because the blood from hemorrhaged vessel leaks-out 
and piles in GI-tract. So, radio-images using technetium-99 m labeled RBCs tracer 
shows the exact pinpoint location of hemorrhage.
After administration, technetium-99 m labeled RBCs speedily disperse in the 
vascular spaces. Small amount to activity could be observed in the urinary tract, 
that is due to free activity. No considerable GI bleeding is visualized in the early 
angiographs. But with time lapse the angiographs shows the bleeding in case of 
hemorrhage (blood move out of the disrupted area and the tracers in blood give 
exact scan of image [5].
The other examples include:
• 111In-DTPA imaging is employed to demonstrate the leakage of cerebrospinal 
fluid.
• Post cholecystectomy, 99mTc-disofenin or 99mTc-mebrofenin could be used to 
monitor whether the bile is leaking out in abdomen or not.
• The 99mTc-MAG3, a peptide, binds 99mTc and could be employed to assess 
reno-vascular hypertension, kidney-transplant, hydronephrosis and urologi-
cal anomalies. 99mTc-MAG3 (mercaptoacetyltriglycine) is also used to track 
leakage of urine into the abdominal cavity. Usually after kidney or urinary tract 
surgeries this complication occurs and urine seeps into the abdominal cavity.
2.1.4 Flow within the compartment
The changes in extent, rate and direction of compartmental flow is the conse-
quence of some pathophysiological changes, that needs to be assessed and treated.
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99mTc-sulfur colloids is preferably used for studying the rate at which gastric 
contents are emptied in the stomach by. The reason why 99mTc-sulfur colloid is 
suited for this study is that it is not absorbed by Gastrointestinal tract. For assess-
ment of solid emptying rate 99mTc-sulfur colloid is bound in scrambled eggs, while 
for liquid emptying rate 99mTc-sulfur colloid is mixed in drinking water. Then 
experimental values are compared to normal values with a margin of ±2 standard 
deviation. The presence and rate of back reflux of contents (due to infections) of 
urinary bladder to kidney is also studied by the scans taken at specific time lapse 
using 99mTc-sulfur colloid (SC). This tracer is implanted by means of a catheter in 
bladder [6].
2.2 Passive diffusion/simple diffusion
Passive diffusion refers to the random motion from higher to lower concentra-
tion of molecules to attain uniformity. Diffusion of tea into water from teabag is 
most common example of passive diffusion. But typically, in a biologic system this 
movement comprises motion of molecules across the membrane. Factors like pH, 
ionization, size of molecule and lipid solubility affect the mobility of molecules to 
move across the membranes.
Lipid solubility is the primary factor as phospholipids, glycolipids, sphingo-
lipids, and sterols are the common types of lipids that make up membranes, of 
which phospholipid is the chief constituent. So, only the molecules that are soluble 
in lipids (lipophilic) could move across the membranes while polar hydrophilic 
molecules could not cross the membrane system.
pH and ionization impact also influence the mobility of molecules, as all mol-
ecules bear different charge (either neutral or charged according to pH). As pH 
varies the ionization state also varies. Like amines maybe neutral at high pH values 
and protonates at low pH values. So, according to the pH of surrounding, molecule 
could not move across membrane when ionized state (hydrophilic), but same 
molecule could pass when in non-ionizes state (lipophilic).
Size of molecules is another important parameter, allowing only molecules of 
certain size to pass through the pores on membranous surface. Generally, the par-
ticles that weigh less than 80 Daltons could pass only, the entry of molecules greater 
than this size is thus restricted.
There are certain characteristics of passive diffusion:
• Concentration gradient is required for this type of movement. The membranes 
in human body segregates this concentration gradient so, in biologic systems it 
is movement across the membrane (from higher to lower concentration).
• It is fast at high conc. Gradient and slow at low conc. Gradient.
• It does not need any sort of input as it is a passive method.
• It is a non-selective process because no carriers or receptors are included in this 
method.
Many radiotracers are localized in the targeted organs by mechanism of pas-
sive diffusion. And its flow is invariably from areas of high tracer concentration to 
lower. Initially, diffusion rate is in direct proportionality to the tracer concentration, 
until equilibrium is achieved. 133Xe,127Xe, and 81mKr are commonly used for ventila-
tion and have non-reactive lipophilic nature. After administering the tracer via 
inhalation, diffusion process operates, and the ventilation gas is scattered in airways 
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of lungs. The flow is smooth until and unless discontinued due to the presence of 
hinderance in airways. After entering the pulmonary circulation, gases leave lungs 
by alveolar-capillary diffusion method.
2.2.1 Mechanism of 99mTc-DTPA (diethylene triamine penta-acetic acid)
A chief factor that has a key role in localization mechanism of radio tracer in 
brain region is barrier of blood and brain (brain–blood barrier/BBB). It is basi-
cally a uniform film of endothelial cells belonging to cerebral vessels, restricting 
the diffusion of lipophobic molecules, and allowing only lipophilic ones. Due to 
some physiological abnormalities, this barrier is interrupted allowing the dif-
fusion of hydrophilic molecules in tissues of brain. Oxygen, electrolytes, CO, 
glucose, water and other smaller molecules diffuses passively in across barrier 
and use active mechanism to move in the neural cells, while immuno-globulins 
(large particles), many lipophobic radiotracers and other lipophobic (hydro-
philic) particles cannot cross the barrier under normal circumstances but in 
situations when barrier is disrupted the radiotracers accumulate at the area of 
tumor/abnormality easily, showing a + scan.
A typical radiopharmaceutical for brain imaging by 99mTc-DTPA. Normally, 
it cannot diffuse across barrier easily because of its lipophobic nature (See 
Figure 1(A)), but in abnormalities like tumor and infections the barrier is 
disturbed, so, 99mTc-DTPA move passively across barrier and amass in the infected 
area of brain (See Figure 1(B)). Its biologic half-life is 1–2 hours, halftime for 
clearance of plasma is 70 minutes and in 24 hours 90% of the tracer is eliminated 
by urinary system.
10–20 millicurie of 99mTc-DTPA is injected intra-venously in the body and after 
an hour scanned via gamma cameras. If the scan shows no agglomeration of radio-
tracer in brain, it means that the barrier is intact, and the tracer was not able to past 
across the barrier. But if the scans show tracer concentration in the cells of brain 
it means the barrier is no more intact and is prevailed by anomalies. So, the tracer 
highlights the affected areas as hot-spots [7].
Other examples:
Other radiotracers that are involved in such type of study (that localize passively 
in brain) are 99mTc-glucoheptonate (GH),123I-serum albumin, technetium pertech-
netate (99mTcO4
−) [9], Thallous chloride Tl-201 [10, 11], Gallium citrate Ga-67 [12].
Figure 1. 
(A) Illustration of intact barrier in the brain cells that do not allow 99mTc-DTPA to diffuse, (B) disruption of 
barrier in the brain cells [8].
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2.2.2 Mechanism of 99mTc- Sestamibi
99mTc labeled cationic, lipophilic tracers like furifosmin, tetrofosmin and 
Sestamibi for myocardial perfusion imaging have been established. 99mTc- 
Sestamibi is some-what similar to cationic 201Tl+ but Sestamibi transport across 
the membrane only involves passive diffusion [13]. In start, it was assumed that 
the uptake of technetium labeled Sestamibi by the myocardial cells is primarily 
because of binding of lipid constituents to the membrane of cell. This ambiguity 
was later cleared that uptake was not because of membrane’s binding to lipid con-
stituent, instead the cellular entry is chiefly linked to mitochondria and its negative 
potential of inner membrane. About 90% of uptake was linked to mitochondria 
[14] (See Figure 2(A)). It was studied that the upholding of technetium labeled 
Sestamibi is not specific to tumor of some organs, rather it is a general mechanism.
99mTc- Sestamibi moves passively from blood to tumor and amass in the cancers 
that have low multidrug-resistant pump expression and more mitochondria mak-
ing cancers susceptible to precise diagnosis. But in most cases, the resistance pump 
dominates over mitochondrial presence making cancers non-susceptible to 99mTc- 
Sestamibi, because the resistance pumps eject the radiotracer out of the cell [15]. 
So, the upholding status of this radiotracer reflects the membrane permeability of 
mitochondria and the mitochondrial potentials. Alterations due to cancers leads 
to dys-functioning of mitochondria that consequently cause decreased uptake of 
tracer [16] (See Figure 2(B)). The decreased upholding of technetium Sestamibi 
in the terms of chemotherapy (after chemotherapeutic session) is correlated to 
the over-expression of multidrug-resistant proteins. So, the cancers which do not 
uphold this tracer are not prone to chemotherapy.
Figure 2. 
(A) Normal binding of 99mTc- Sestamibi to mitochondria, (B) over-expression of resistance pump that quickly 
removes 99mTc-sestamibi out of cell, (C) effect of Bcl-2, an anti-apoptotic protein; that halts the binding of 
99mTc-sestamibi to mitochondria [17].
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Figure 3. 
Phagocytosis process through macrophages of liver (Kupffer cells) present in the lining of liver [20].
The other possibility is that the protein that prevents the induction of apop-
tosis (Bcl-2, prevents the membrane permeability of mitochondria) maybe over 
expressed, halting the entry of radiotracers in mitochondria [18] (See Figure 2(C)).
Few compounds to suppress/neutralize the effects of anti-apoptotic protein have 
been subjected to clinical trials. The purpose for this is to monitor the credibility 
and efficacy of ongoing therapeutic procedure.
2.3 Phagocytosis
The word “Phagocytosis” derived from Greek language that translate as “CELL 
EATING” (a procedure in which cell engulfs a particle and internalizes it). A prime 
example involves Kupffer cells (that present in the lining of liver and involve in the 
breakdown of red blood cells also known as phagocytic cells) in the reticuloendothelial 
system entrapped the radio-labeled colloidal particles following an intravenous injec-
tion [19]. The particle size of radiolabeled colloidal suspensions is usually between 0.05 
to 4 μm. 99mTc-macro-aggregated albumin and 99mTc-sulfur colloid are mostly used as 
phagocytic agents and their size ranging from approximately 0.1–2.0 μm are able to 
leave the circulation via the sinusoidal type capillary structures in the liver, spleen, and 
bone marrow [20]. There is inverse relation between particle size and its bone marrow 
uptake that is why the larger particles will localize in spleen and liver.
The diameter of capillary is about seven micro-meters which is larger than par-
ticle size, capillary blockade does not occur. Opsonin (serum specific protein) may 
interrelate and provide coating to the colloids so that may be recognize by receptors 
site; then, engulf and removed from circulation by cells of the reticuloendothelial 
system as shown in Figure 3 [21].
Macrophages in liver sinusoids (Kupffer cells) and macrophages in spleen (reticular 
cells) accumulate the particles by phagocytosis. In a liver scan with 99mTc-sulfur colloid 
cold lesions identified may be due to intra hepatic tumor displacing normal distribu-
tion of reticuloendothelial system’s cells. Similarly, decreased reticuloendothelial 
system functioning may appear as radiation damage in bone marrow and liver shown 
as cold areas in scan results. Patients having melanoma and breast cancer, 99mTc-SC has 
been widely used in lympho-scintigraphy for the identification of sentinel node which 
is the first lymph node to receive lymphatic drainage from tumor cells [22].
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Distribution in the endothelial system is typically Five percent in marrow, Ten 
percent in spleen and eighty-five percent in liver. The tbiol of macro-aggregated 
albumin is 6–12 hours which is infinitely short as compared to tbiol of 
99mTc-sulfur 
colloid in the liver. T ½ of clearance from the blood pool is 2.5 min; so, in approxi-
mately ten minutes only 6% remains in blood stream. Imaging must begin after 
5–10 minutes of intravenous colloidal injection [23].
The radiopharmaceutical, Tc-99 m sulfur colloid, is localized by this mechanism 
used for liver scans. Cyst, tumor abscess or hemangioma are focal areas of lacking 
phagocytic cells will be demonstrated as “Areas of lack uptake”. There will be a col-
loid shift if liver is poorly functioning such as with cirrhosis or hepatitis [22, 24].
2.4 Capillary blockade
This technique most precisely depends upon the phenomenon of micro-
embolization (trapping the radiolabeled particles in the capillary bed) used to 
determine perfusion of organ such as brain, heart, and lung. For pulmonary 
perfusion studies commonly used radiolabeled particles is Technetium labeled 
macro aggregated albumin particles. 99mTc-MAA particles have diameter of about 
10–50 μm while, pre-capillaries and capillaries have a mean diameter of 20–25 μm 
and 8 μm, respectively. Therefore, intravenous injection of 99mTc-MAA particles 
block the blood flow to the distal region of lung by physically trapped in arterio-
capillary beds as shown in Figure 4 [19, 25].
Smaller particles pass through the pulmonary capillaries and are extracted by 
the reticuloendothelial system in the body. Therefore, the mechanism of localiza-
tion of particles in lungs is purely a mechanical process, called capillary blockade. 
In experimental animal studies, gold standard for determination of organ perfu-
sion is radiolabeled microspheres with varying particle diameter and physical 
half-lives [27].
The first encountered capillary beds are the lungs when such sized particles 
injected intravenously. For perfusion lung scan radiolabeled particles (Tc-99 m 
Figure 4. 
Illustration of capillary blockade due to 99mTc-MAA accumulation in capillary beds [26].
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Figure 5. 
Schematic explanation of 99mTc-DRBC preparation [30].
macro-aggregated albumin) have been used. This delivery mechanism necessar-
ily involves to the capillary beds via blood flow, localization of Tc-99 m MAA is a 
surrogate for relative blood flow in lungs. Therefore, this perfusion lung scan with 
Tc-99 m MAA aggregates also used to assess blood flow in pulmonary arteries. A 
similar procedure in which Tc-99 m MAA is injected in hepatic artery through a 
catheter, it is delivered via hepatic blood flow to the capillaries in the liver [19, 28].
2.5 Cell sequestration
Potentially saturable mechanism that is mostly associated with spleen and refers 
to the process where damaged and old RBC’s removed from circulation [29]. It is 
unlikely for the relatively small numbers of cells used for imaging. The radiophar-
maceutical preparation is carried out by in vitro labeling of red blood cells with 
technetium-99 m using modified Brookhaven labeling method and then damaging 
them by heating at 49°C for fifteen minutes (Figure 5).
2.6 Ion exchange
Ion exchange is a mechanism of localization in which ions exchange between a 
complex like hydroxyapatite and electrolyte solution. 18F radioisotope is typically used 
for imaging metastatic and primary tumors present in bone. In 18F-NaF the mechanism 
of localization followed by this radiopharmaceutical is Ion exchange mechanism and 
is used for studying metabolism of bones and also for bone imaging [19]. 18F obtained 
from cyclotron is diluted by using 5 mL of sterile water and then passed through a 
sealed unit containing cation exchanger and then anion exchanger. To obtain 18F-NaF, 
10 ml saline (NaCl) is added in anion exchanger. And then eluted 18F-NaF from anion 
exchanger is ready to inject in patients. The localization mechanism of 18F-NaF in 
infected area involves the exchange of fluorine anion (F−) from hydroxyl group (OH−) 
in hydroxyapatite a bone crystal [Ca10 (PO4)6 (OH) 2]. After the exchange of F
− with 
OH−, fluoroapatite [Ca10 (PO4)6 (F) 2] is formed as shown in Figure 6 [1].
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When 18F-NaF injected in the body of patient its distribution depends on the 
blood flow of body and the amount of 18F-NaF distributed in different bones at 
different ratio. In bone marrow the uptake of radioisotope is almost negligible. 18F-
NaF can easily diffuse through membrane and almost 30% radiotracer present in 
erythrocytes. 18F-NaF has a fast plasma clearance rate. For bone deposition 18F-NaF 
must pass through extracellular fluid with the help of plasma. The incorporation of 
fluoroapatite in bone in a slow process and it depends on the area of infected bone. 
In case of malignant bone disorder, the incorporation time of fluoroapatite is high. 
Fluoroapatite has low binding with plasma protein and rapidly clear from non-
targeted area. After 40–45 minutes of radiotracer injection, fluoroapatite permits 
the whole body imaging [32].
2.7 Chemisorption
Chemisorption also known as physiochemical adsorption is localization 
mechanism refers to the binding of phosphate-type compounds like methylene 
diphosphate (MDP), pyrophosphate (PYP) and hydroxy diphosphate (HDP) onto 
the bone surface. So, with the increase in bone metabolism like tumor, fracture 
and infection, surface area increases and hence there is enhanced accumulation of 
radiopharmaceutical at that surface. 99mTc-MDP, 99mTc-PYP, and 99mTc-HDP all bind 
to tissues of bone by this mechanism [19].
The administration of radiopharmaceuticals with low-energy photons that 
are attached chemically to moiety having affinity with hydroxyapatite a bone 
mineral. This attachment permits selective radiation dose to the area of interest 
with no or minimum radiation dose to the non-infected tissues. Out of 100%, 
only 40–50% dose of injected radiopharmaceutical localizes in bone and the 
remaining 50–60% dose is excreted from body through kidneys. Since, the 
Figure 6. 
Ion exchange mechanism of 18F-NaF for bone deposition [31].
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radiopharmaceutical uptake in bone is low, so imaging starts after three hours of 
post injection [33].
2.7.1 Chemisorption mechanism of 99mTc-PYP
99mTc-PYP is used for the acute myocardial infarction imaging is an example 
of Chemisorption mechanism of localization. Myocardial infarction starts when 
myocardial cells turn out to be necrotic, calcium ions influx create into the cells. 
Circulating phosphate ions present in body reacts with the Ca2+ ions and Ca3 
(PO4)2 crystals are formed. Resulting calcium phosphate crystals formed hydroxy-
apatite present on bone tissues. 99mTc-PYP binds irreversibly and avidly to calcium 
phosphate crystals at the infarct periphery where some perfusion is maintained as 
shown in Figure 7. After two hours of post injection imaging takes place [34].
2.8 Filtration
Filtration is denoted as a significant case of diffusion in which carrier molecules 
are compelled to progress by an osmotic or hydrostatic pressure gradient through 
several channels and pores. The significant example of this process explained is by 
glomerular filtration of kidney. Radiopharmaceuticals are effectively employed in 
renal imaging and in the determination of renal morphology or renal functioning. 
Two physiological mechanisms such as glomerular filtration and tubular secre-
tion are accountable for renal imaging. Agents cleared by glomerular filtration are 
further utilized in investigating the glomerular filtration rate (GFR) [19].
Figure 7. 
Systematic representation of chemisorption of 99mTc-PYP [35].
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There are two factors that are primarily concerned for the glomerular filtration 
of kidney comprising radiopharmaceuticals. First factor is the availability, only 
those molecules are liable for filtration that are freed in plasma and are not protein 
bounded. Second factor required for glomerular filtration is the pore size versus 
molecular size. Usually, only small hydrophilic molecules having a size less than 
5000 are capable of disseminating through glomerular pores [36].
Some other factors are also involved in this glomerular filtration mechanism. 
Some pressure gradient or force is necessity for filtration while in the case of glo-
merular filtration, this specified force is provided by blood pressure however it does 
not demand any indigenous involvement of external output or energy. Moreover, 
filtration is non-selective due to the non-involvement of any receptors, transporters 
or carrier molecules [37].
Various radiopharmaceuticals are excreted partially by glomerular filtration, but 
the radiopharmaceutical most employed for renal imaging glomerular function is 
Tc-99 m DTPA. Renal DTPA can be determined from estimating the activity in mul-
tiple or single blood samples, the elimination of activity from tissue or blood and 
from the emergence of tracer particles in urine [19]. Example of Filtration process is 
depicted as shown in Figure 8.
Some other radiopharmaceuticals excreted indigenously during glomerular 
filtration are 99mTc- MAG3 and EC (ethylene di-cysteine) for tubular secretion, 131I 
and 123I for Tubular (80%) and glomerular (20%), 99mTc-DMSA for cortical binding 
(50%), and 99mTc-GHA for cortical binding (20%) and glomerular filtration (80%) 
as shown in Figure 9.
2.9 Active transport
Active transport is carrier mediated, metabolic, energy dependent pathway in 
a body to move forward a radiopharmaceutical across a cell membrane into a cell. 
The energy utilized during this reaction comes from ATP that allows the trans-
port of molecules against a concentration gradient. It is carrier selective, which 
explicates fitting of small number of molecules into a specific carrier and makes 
it possible to accomplish saturation i.e. maximum response provided when all the 
carriers are engaged [19].
Figure 8. 
Pre-treatment was done with captopril (an ACE inhibitor used for decreasing pressure on blood vessels), 
glomerular filtration of Tc-99 m DTPA is decreased as seen in the left kidney (arrow). Captopril employed, 
blocked the compensation mechanism triggered by left kidney ensuring a decreased pressure in the left  
kidney [19].
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Concentration of iodide in the thyroid gland is an eminent example of active 
transport. Iodide ions are conveyed into thyroid cells by the Na+/I− symporter. 
Therefore, I-123 and I-131 (radioisotopes of iodine) are suitable radiopharmaceu-
ticals to assess thyroid functioning [3]. Furthermore, Tc-99 m pertechnetate has 
almost same negative charge and ionic radius, hence it is too transported like iodide 
as shown in Figure 10.
It is highly significant that high concentrations of iodide (in the form of injec-
tions of iodinated contras media) in the blood, will competitively prevent thyroid 
uptake of these radiopharmaceuticals. Firstly, iodide is trapped producing an 
intermediate thyroglobulin and is eventually converted into T3 & T4. Preliminary, 
localized in thyroids, parotids and stomach and ultimately cleared through kidneys 
as shown in Figure 10 [39].
Figure 10. 
(A) Regular uptake of Tc-99 m pertechnetate in thyroid (and salivary glands). (B) Absent uptake of thyroid 
(arrow) of Tc-99 m pertechnetate in an iodinated x-ray contrast media administered patient a few days 
earlier [19].
Figure 9. 
Different mechanism of renal radiopharmaceutical excretion and uptake, including glomerular filtration, 
cortical binding and tubular secretion [38].
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Glucose absorption from the GI tract into the blood and then reabsorption of 
glomerular-filtered glucose back into the blood by the distal renal tubules is another 
example of active transport. A sodium-dependent glucose cotransporter (SGLT) 
is employed to perform this function. Even though F-18 FDG is not voluntarily 
transported by SGLTs, glomerular filtered F-18 FDG residues in the urinary tract 
and flows to the bladder. Eventually, F-18 FDG do not perform the same function as 
glucose that is being reabsorbed into the blood [19] (Figure 11).
A third example of active transport is the Na+/K+ (sodium/potassium) pump, 
due to its significance in the heart muscle. Thallous chloride has extensively 
employed for myocardial perfusion scans. However, due to similar ionic size of 
thallous ion as potassium ion, it fits in place of potassium ion in sodium/potassium 
pump. Therefore, heart muscles reflect coronary perfusions.
Figure 11. 
Following injection of F-18 FDG in a normal patient, there is high uptake in brain, variable uptake in heart 
(high uptake in this patient), and moderate uptake in liver, GI tract, and marrow [19].
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A second radiopharmaceutical is rubidium chloride which falls just below the 
potassium in periodic table has somewhat similar properties and fits in sodium/
potassium pump, thus utilizing for PET myocardial perfusion scans [39].
2.10 Facilitated diffusion
A type of carrier-mediated transport across membranes is known as facilitated 
diffusion. Essentially, a carrier is utilized to carry the molecule across the mem-
brane so, it is a selective carrier membrane (i.e., only certain molecules fit into the 
carrier). Consequently, it is inhibited by the presence of similar molecules that also 
fit into the carrier. Saturation can be achieved to maximum due to limited num-
ber of carriers. Facilitated diffusion expends passive so it entails a concentration 
gradient for its functioning. However, external energy is not employed in facilitated 
diffusion.
Glucose is the key example of facilitated diffusion. Glucose move into the cells 
by transmembrane protein transporters [GLUT]. Similarly, radiolabeled analog of 
glucose F-18 fludeoxyglucose (FDG), goes into the cells via the glucose transporters 
[GLUT]. After entering the cell, both glucose and FDG are phosphorylated by hexo-
kinase. Glucose-6-phosphate then enters the glycolytic pathway. But the metabo-
lism of FDG-6-phosphate is further blocked, so FDG is reserved in the cells. It is 
significant to summon up that glucose and FDG are competing for GLUT transport-
ers, consequently prominent blood levels of glucose will reduce the cellular uptake 
of FDG [19] (See Figure 12).
2.11 Cellular migration
A physiological migration directed by cell especially in response to some stimuli. 
The principle example is taxis of WBCs in response to inflammatory chemokines and 
cytokines. Ex-vivo labeling of 99mTc-HMPAO and 111In-oxyquinoline with phagocytic 
Figure 12. 
Glucose and FDG transported inside cell, phosphorylated by hexokinase. 18F-FDG-6-phosphate did not 
metabolized further but glucose-6-phosphate continue metabolism in cell mitochondria. Tumor cell, ischemic 
myocytes and macrophage acquired more 18F-FDG [45].
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leukocytes (mainly neutrophil) are frequently used complexes for infection and 
sterile inflammation site studies. Physiologically, autologous leukocytes chemotacti-
cally migrate towards pathogens in fact studies extended the use of leukocytes for 
radiolabeling that not only invade pathogens but also diagnose infection foci. At least 
2000 or more leukocyte per microliter should be labeled for better quality image 
[40]. Labeled leukocytes were mostly neutrophil so that these complexes more 
sensitive to the neutrophil mediated infections. The uptake and rate of migration of 
radiolabelled cells depends upon the site of infection, virulence, stage of infection, 
kind of pathogen, upon antibiotic therapy and angiogenesis of tissues [41].
Ex-vivo labelling of 111In- oxyquninoline with leukocytes was initiated by 
McAfee and Thakur [42]. The 111In-oxine was neutral, lipid soluble, non-specific 
blood cells labeling agent that passively penetrate through bilayer membrane and 
bind with cytosol component (lactoferrin; iron bounded protein released by neu-
trophil). The lactoferrin bind with indium more firmly than oxine and free oxine 
(8-hydroxyquinoline) leave the cell environment. Scintigraphy using 111In-oxine 
(8-hydroxyquinoline) with labeled leukocytes (WBCs) were the clinically proved 
agent of choice for detecting infection foci accurately [43, 44].
Approximately after 1 hour of injection, about 60% radioactivity of indium 
labeled leukocytes were found in the lungs and if not damaged migrate to liver, 
spleen, bone marrow and reticuloendothelial system. In case of infection, radio-
labeled WBCs accumulate at the site of infection due to chemotactic attraction of 
biofilms and other soluble products of bacteria. The reason for the regular usage of 
111In- leukocyte for tumor imaging were its stability, normal body distribution and 
complementary bone marrow imaging as shown in Figure 13. The cons of complex 
are its lower sensitivity in infection that cannot elicit the neutrophil response e.g. 
tuberculosis and about 18 to 30 h delay in injection administration and imaging [40] .
Figure 13. 
Depiction of tumor cell microenvironment. 111In-oxine labeled with leukocytes. Leukocytes move within blood 
stream and act as first line of defense. Attached radiotracer (111In) image tumor cell microenvironment [45].
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111In-oxine labeled leukocytes preferably practiced for the diagnosis and therapy 
of inflammatory bowel disease, osteomyelitis, abdominal infection, diabetic foot, 
vascular prosthesis, pelvic sepsis, lung infection, fever of unknown origin, neuro-
logical infection, and endocarditis etc. Furthermore, for the ex-vivo radio-labeling 
sterile conditions should be taken because there was a possible risk of cross con-
tamination that may be tainted with hepatitis B, C or HIV.
99mTc- exametazime (HMPAO) labeled with autologus leukocytes (predomi-
nantly neutrophils) follow the same pathway for infection and inflammation imag-
ing as 111In-oxine labeled leukocytes. Neutrophil, an important part of our innate 
immune system moved towards acute infection foci and invade pathogens [45]. 
Labelling of leukocytes followed by intervenously administration of radiolabelled 
complex, due to inflammatory cytokines and chemokines; WBCs were attracted 
towards infection site. The 99mTc-leukocyte detect abnormalities soon after the 
injection and image not only reticuloendotelial system but also visualize urinary 
tract, bowl and gall bladder. Limitation includes the short half life of 99mTc and 
delayed bone marrow imaging (2 to 3 days between leukocyte imaging and bone 
marrow imaging) [40].
Platelets; an important part of thrombus formation, when labeled with 111In 
can follow simple cell migration mechanism to incorporate inside active thrombus 
formation so that easily picturize the thrombus formation. Heat damaged 99mTc-
RBCs taken up for the examination of splenic nodule tissue formed after splectomy. 
During circulation of old and new RBCs, the old and damaged one was sequenter 
in the spleen. In same way heat damaged labeled RBCs sequenter inside spleen and 
imaged accessory spleen tissues [45].
3. Infection imaging agents based on metabolic activities
Tumor cells have higher metabolic rate as compare to the normal body cells, this 
upreglate the metabolism of cells and trap more molecule per gram than normal 
somatic cells. Through different metabolic ways like enhanced glucose metabolism 
for harvesting more energy. Following mechanism involved in proliferating cell 
metabolism and
• Sugar metabolism
• Iron metabolism
• Amino acid metabolism
• Lipid metabolism
• Thymidine kinase activity and folic acid synthesis
• Imaging cell micro-environment through Hypoxia and acidic pH
3.1 Sugar metabolism
Cancerous cells proliferate rapidly and get more energy to fulfill physiological 
activities. Glucolysis is the preliminary energy driving metabolism. What would 
happen if the same metabolism used for imaging cell?
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3.1.1 Deoxyglucose
An analogous molecule of glucose but not sugar it has one oxygen atom less 
than glucose. Fluorine (F- 18), a cyclotron based radionuclide labeled with glucose 
analogous (deoxyglucose) through nucleophilic reaction with mannos triflate 
(precursor) [2]. 18F-FDG (fluorodeoxyglucose) practice for clinical oncology since 
1980s [46]. The fluorodeoxyglucose participate and transport inside cell by follow-
ing the same pathway as glucose through glucose transporter; GLUT-1. This glucose 
transpoter GLUT-1 release in stress condition and a member of glucose regulating 
protein [45]. As said earlier deoxyglucose is a glucose analogous, so this analogous 
molecule metabolized by the same pathway as glucose and was trapped in place of 
glucose molecule and get phosphorylated (glycolysis) as shown in Figure 12.
Glucose-6-phosphate further participate in glycolysis but FDG-6- phosphate 
cannot metabolized (not being the subsequent substrate) as glycolytic enzyme 
glucose-6-phosphate isomerase (hexokinase) has strict structural and geometric 
demands so fluorine substituted; 2-oxy-2-fluoro-D-glucose trapped and accumulate 
inside cell cytoplasm (metabolic trapping) [44]. Remember that glucose and FDG 
compete for the same transporter GLUT-1, so higher glucose level may lower the 
uptake of FDG. The enzyme hexokinase may convert back fluoro-6-phosphate to 
FDG but cancerous cell have very low amount of this enzyme so this trapped mol-
ecule (18FDG-6-PO4) aid in-vivo study of homeostatic system without disturbing 
their function. 18F-FDG is presently the most widely used PET tracer for imaging 
non-invasive malignant tissues that highly metabolized glucose [45].
The 18F-fluorodeoxyglucose participate in imaging of osteomyelitis, spinal 
infections, endocarditis, infected joint prosthesis, diagnose FUO and diabetic foot 
infection. Limitation regarding 18F-FDG use that it cannot differentiate between 
infection and sterile inflammation.
3.1.2 Sorbitol
Another alcohol soluble sugar; sorbitol, act as a metabolic substrate for bacterial 
specific imaging. Gram negative bacterial strains (Klebsiella pneumoniae, Escherichia 
coli, Yersinia pestis, Enterobacter spp., etc.) show promising findings but limited 
detection in case of Gram-positive bacteria and mammalian cancer cells. Sorbitol 
was taken up by the bacterial surface membrane transporter, then phosphorylated 
and metabolized in the same manner as glucose. Initially 18F-FDG reduce to 18F-
FDS (fluorodeoxysorbitol) as shown in Figure 14 than transported to bacterial cell 
environment where analogous glucose metabolism begin next [47]. Interesting fact 
is that mammalian cells did not have transporter for this sugar [43]. Moreover, 18F-
FDS act as promising agent in PET imaging for monitoring efficacy of antibacterial 
burden and proved to be safe for intravenous human use that determine radiation 
dosimetry and cell biodistribution [48].
3.2 Iron metabolism
For the development of new radiopharmaceuticals similarities with ferric ion 
(Fe+3) was very important as iron is a fundamental part of our body and many iron 
binding proteins likewise transferrin, lactoferrin and ferritin transport and store 
iron in-vivo. 67Ga++ ion produced at physiological pH its infection uptake is multi-
factorial since it shares similar chemical characteristic and biodistribution proper-
ties with ferric ion (Fe+3). When 67Ga- citrate administrated in blood plasma due to 
the increase cell permeability and blood flow about 90% activity exchange ligand 
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with plasma protein in extracellular space. Therefore, iron atom always competes 
with radio-metal (67Ga) for binding with plasma protein. 67Ga-citrate exchange 
ligand with transferrin protein in cell plasma. Cancerous cells overexpress cell 
proliferation and metabolic activities, to meet the cell membrane receptors demand 
tumor and inflammatory cell membranes have ubiquitous membrane receptors on 
them. In fact, infinite transferrin receptors are getting to the cell having rapid cell 
growth and upregulated DNA synthesis (like tumor and inflammatory cells), thus 
ensuring more uptake of 67Ga++.
67Ga-citrate localize non-specifically at the site of infection where the 
67Ga-transferrin complex formed due to the leakage of plasma protein from blood 
vessel to extracellular space of inflamed tissues. The acidic environment of inflam-
matory interstitial tissue space has more lactoferrin another plasma protein secreted 
by stimulated or dead neutrophils, which subsequently tie with 67Ga due to higher 
ionic attraction [2]. Another 67Ga uptake mechanism seen in bacterial infection, 
a 67Ga-avid, direct attachment of 67Ga with bacterial siderophores (specific pro-
karyotic metal chelating peptides) [49]. Some gallium atoms also transported by 
circulating WBCs [40].
67Ga-citrate used primarily for the diagnosis of spondylodiskitis, moreover for 
benign and neoplastic lymphomas particularly in evaluating staging, prognosis 
and follow up imaging of residual disease. Though 67Ga-citrate not being specific 
for bacterial infection and replaced with 18F-FDG/PET but still 67Ga-citrate are 
widely used to identify the site of FUO and worthwhile in nuclear oncology 
(Hodgkin’s and non- Hodgkin lymphoma) [2, 43, 50]. Disadvantages of 67Ga may 
include its short physical half-life (t1/2 = 68 min), uptake in inflammation and 
trauma [40].
3.3 Amino acid metabolism
Amino acids and proteins are the key elements in building block of life. Amino 
acid actively transport and uptake greaterly in the proliferating cancerous cells 
which reflects the increase synthesis of protein. Methionine, an essential natural 
occurring amino acid customize as l-[methyl-11C] methionine and potentially 
used in PET oncology. Additionally tyrosine, another essential amino acid analog 
frequently used as radiolabelled tracer. As these tyrosine tracers not involved in 
protein synthesis [11C] methyl-1-tyrosine,O-(2-[18F] fluoroethyl)-L-tyrosine (FET), 
1-[2-18F] flourotyrosin, 1–4-[18F] fluoro-m-tyrosin and 1-[3-18F]-a-methyltyrosine 
(FMT), these analogs used in evaluating brain tumors, neuroendocrine tumors, 
prostate and pancreatic cancer uptake [45, 51, 52].
3.4 Lipid metabolism
The upregulation of glycolysis, iron and amino acid metabolism in cancer-
ous cells also characteristically agitate the lipid production. During normal 
Figure 14. 
Reduction reaction of 2-Deoxy-2-[18F] fluoro-D-glucose to 2-Deoxy-2-[18F] fluoro-D-sorbitol using NaBH4 
reducing agent.
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conditions production of triglycerides combined with long term energy reser-
voir. Cancerous cells do not manage the cell energy requirement with primary 
source; carbohydrates. So they preferentially employed lipid metabolism to 
meet energy requirement by producing more essential membrane phospho-
lipids and phosphatidylcholine [46]. As a result two essential lipid production 
enzymes fatty acid synthase (FAS) and choline kinase (ChoK) overexpressed 
in lymphomas including breast, lung, colon, ovarian, and prostate cancers. So 
in lipid de novo synthesis FAS catalyze the acetic acid reaction for the synthesis 
of phospholipid phosphotidylcholine and choline kinase responsible for phos-
phocholine production as shown in Figure 15. Fatty acid radiolabelled analogs 
[11C]- Acetate, [11C]-Choline, [18F]-Fluorodeshydroxycholine [18F]-Choline, 
[18F]-Flouoethycholine used in PET oncology imaging of brain tumors, liver 
tumors, prostate and breast malignancies [53, 54].
3.5 Thymidine kinase and folic acid synthesis pathway
Thymidine kinase; a metabolic substrate that catalyze the conversion reaction 
of nucleoside subunits to nucleotide units and then use these units in the synthesis 
of DNA. These labeled bacterial substrate initialize for SPECT [125I]-FIAU and PET 
[124I]-FIAU imaging. Thymidine based PET radiotracers [11C] TdR, [18F] FLT, [18F] 
FMAU and [76Br] FBAU [46, 57].
Folic acid; another metabolic salvage for nucleic acid synthesis (subsequently 
DNA synthesis) in prokaryotes. Para aminobenzoic acid (PABA) responsible for 
the folic acid production in microorganism and this substrate labeled with radio-
tracer [18F]-PABA/PET. This radiofluronated analogues [18F]-PABA holds potential 
for clinical translation in bacteria and poor attraction with mammalian cells [58].
Figure 15. 
De novo fatty acid synthesis mechanism using acetate substrate [55, 56].
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3.6 Oxidative metabolism (tissue hypoxia)
Hyoxia, a phathophysiological condition portray deprived of adequate oxygen 
level in tissues. A normoxic cell have oxygen level 20–80 mmHg compared to 
hypoxic cell <3 mmHg. In malignancies, irregular vascularization cause ischemic 
hypoxia. The severity of cancerous hypoxia depend upon tumor phenotype for 
example cervical cancer has severe hypoxic injury. Hypoxia may alter the function 
in tumor microenvironment particularly angiogenesis, vasculogenisis, apoptosis 
and prospensity for metastasis [46].
Potential hypoxia selective PET radiotracer has been developed to evaluate 
tumor microenviroment.18F-fluoromisonidazole (FMISO) and 64Cu-[4-N-methyl-3- 
thiosemicarbazonato ligand] (ATSM) translated for hypoxia imaging [59].
4. Cell proliferation
Tumor specific radiolabeled drugs are now clinically approved for non-surgical 
treatment and molecular imaging of malignant growth of cells and definite modifi-
cations were implemented to make possible radionuclide therapy of cancerous cells. 
Uptake, delivery and retaining mechanisms of radiolabeled drugs in targeted tissues 
and organs involve many ways which are of particular importance [60]. Normally, 
cells and tissues maintain a consistency between cell proliferation and cell death. 
On the other side, carcinogenic cells promote cell growth. In addition, amplified 
mitotic rate, increased cell growth and reduced differentiation are responsible for 
enhanced cell propagation. Generally, progression rate of cancerous cells depends 
upon the differentiation levels of benign and malignant tissues that leads to 
advanced mitotic rates [61] (Figure 16).
The idea of localization of radiolabeled drugs at tumor sites is best described 
in terms of transformed physiology of specific proliferating cells. Such localiza-
tion should take place in correlation with diseased parts of the body including 
external and internal regions of infected areas [63]. Tumor targeting involves 
a certain type of interaction between medication and its receptors at affected 
tissue site. Malignant tumors required excess quantity of nutrition and release 
certain receptors which, in contrast, used as carriers to distribute cytotoxic 
agents as shown in the above figure. Larger number of rapidly producing cells 
were compared with normal cells during cell cycle i.e. S-phase. Consequently, 
substrate requirement in the form of nucleotides for DNA synthesis was also 
increased. This nucleotide incorporation into DNA of tumor cells is determined 
using thymidine to measure the number of proliferated cells. 11C-labeled thymi-
dine has been utilized as PET radiotracer to image head and neck. Furthermore, 
Figure 16. 
Difference of cell surface receptors in normal and tumor cells [62].
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targeted drug delivery systems necessitated drug localization and carriers within 
the desired organ.
In diseased patients, diagnosis and evaluation of therapeutic response is accom-
plished with positron emission tomography (PET). Studies based on this technol-
ogy seek imaging mediators with eminent tumor selectivity and specificity for 
distinct attributes [64]. In 1950s, procedures were considered to estimate quantity 
of thymidine integrated into DNA of malignant tissues by using 3H-Thymidine. 
Meanwhile, in 1972, 11C-labeled thymidine was evolved in molecular imaging to 
approximate cell growth. Nonetheless, rapid metabolic rate of this radiolabeled 
drug makes it less convenient for repetitive imaging practice.
18F- 3′-deoxy-3′-fluorothymidine (FLT) is significantly developed radiotracer 
for molecular imaging techniques to investigate cell proliferation as it provides 
prolonged time interval so that there will be less quantity of labeled metabolites and 
scanning tissues will be cleared off catabolic waste. Transportation of FLT takes place 
into cell through distinct transporters and enzymatic action of thymidine kinase 
1 (TK1) phosphorylated radioactive tracer into 18F-FLT monophosphate that got 
trapped into cell. Moreover, PET images demonstrate additional phosphorylation into 
FLT-TP by enzyme thymidylate kinase. Reaction end products are then metabolically 
stuck within cells due to membrane impermeability and resistant to mortification.
FLT has greater potential to evaluate the status of malignant cells for thera-
peutic purposes. Diverse range of melanoma tissues i.e. breast, lung, head, neck, 
lymphoma and gastrointestinal have been analyzed by means of fluorine labeled 
thymidine [65]. Finally, 18F-FLT is under evaluation and measurement of anticancer 
therapeutic response.
18F-florouridine as a nucleoside analogue illustrates localization by cell pro-
liferation but the radiopharmaceutical also incorporated into DNA and RNA of 
tumor tissues. 11C-thymidine was considered to observe multiplying tumor cells 
but prompted catabolic rates create hindrance in drug uptake volume and leads to 
complex imaging due to interfering catabolites (radiolabeled). 18F-1-(2′-fluoro-
2′-deoxy-β-D-ribofuranosyl) thymine (FMAU), a fluorine labeled analog of 
advanced stability with favorable results in animal cells. Phosphorylated complex 
incorporated into DNA to examine cell proliferation. Radioiodine I-131 & I-123 
labeled metaiodobenzylguanidine (MIBG) represent the potent radioactive drug 
with diagnostic and therapeutic response to treat metastatic tumor. Even though, 
peptide receptors are now interchanging radiotherapy of neuroendocrine tumors, 
but the labeled drug still used to treat chromaffin tumors. Following 11C-labeled 
amino acid analogs, 11C-L-methionine and 11C-5-hydroxytryptophane, are used 
to visualize breakdown rates of cancer cells and imaging of different phases of 
thyroid tumors.
An analog of dihydroxyphenylalanine, 18F-DOPA, stored in brain tumor 
cells and exhibit amino acid transportation.18F-labeled synthetic amino acids 
i.e. L-leucine derivatives, 18F-fluoro-cyclobutyl carboxylic acid (FACBC), are 
preferentially firm and rigid with extended time frame of uptake by prostate tumor 
[66] (Figure 17).
18F-fluoroethyl tyrosine (FET) localized in brain tumor cells and help to 
determine the type of therapeutic treatment and fate of proliferating tissues. 11C 
and 18F labeled pyrimidine analog, 2’-Fluoro-methyl-D-arabino-furanosyluracil 
(FMAU) considered worthwhile for examining multiplying tumor cells. FMAU 
stored in the cancerous cells, phosphorylated and incorporated into DNA by 
enzymatic action of DNA polymerase with the potential to image DNA replication 
in normal and cancerous cells [68].
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5. Specific receptor binding
Receptors are attachment sites for ligand molecules i.e. polypeptide hormones 
and neurotransmitters. In case of antigen–antibody complex formation, antigen 
expression on cell surface is considered a definite receptor site for antibody bind-
ing. Antigen fragments are present on the upper surface and within the cells or 
sometimes released into body fluids. Localization of definite receptor-binding 
radiotracers depends upon multiple factors such as blood clearance, affinity of the 
tracer & receptor and blood flow of the tumor tissue. Receptors are of various types 
with specificity of basic compound including peptides, steroid hormones, and 
antibodies.
5.1 Somatostatin receptors
Naturally, existing somatostatin (SST) complexes of peptide formation are of 
two types. One with 14 amino acids (SST14) and other with 28 amino parts and 
designated as SST28. In human beings, SST receptors have been recognized on cell 
surface of neuroendocrine region and on lymphocytes. Seglitide and somatuline are 
synthetically prepared somatostatin analogs with more stability than SST14 because 
the latter one join SSTR sub-types with equivalent association. To image growing 
SSTR cells, iodine labeled octreotide radioactive tracer pioneered the functioning of 
radiolabeled peptides [69] (Figure 18).
Figure 17. 
Pathophysiological mechanisms of significant radiotracers used in investigation of malignant cells [67].
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• 111In-DTPA-pentetreotidewas developed with specific amounts of 111In (10 μg) 
but showed short residing time as released from body circulation via kidneys 
(approximately 50% in 5 h). After that, 90Y-DOTA-octreotide was formed with 
the similar capacity to bind proliferating cells revealing SSTR type 2.
• 99mTc-P829 peptide exhibited peculiar binding ability with SSTR types show-
ing the potential to image rapidly growing cells. The radioactive product is 
FDA approved to image lung cancerous cells [71].
5.2 Vasoactive intestinal peptide (VIP) receptor
A 28 amino acid neuroendocrine moderator with diverse variety of biological activ-
ity in various cells and tissues. Although, receptors of cell membrane are extensively 
present along gastrointestinal tract. However, few receptor cells found on adenocarci-
nomas, malignant tumors, neuroblastomas, and pancreatic cancerous cells.
123I-VIPwas formulated with extraordinary activity ratio of radionuclide of 
about 200 MBq/μg of product to be specifically localized in liver, lung, pancreatic 
and gastrointestinal malignant cells [72].
5.3 Steroid hormone receptor
Steroid chemicals such as estrogen and progesterone have high binding affinity 
with intracellular receptors which are used to identify hormone dependent prolifer-
ating cells in case of breast cancer. Various types of hormonal analogs radiolabeled 
with PET imaging radiotracers. 18F-fluoro-estradiol (FES), with specificity for 
estrogen hormone, has revealed greater potential for analyzing metastatic tumor 
cells. 123I-methoxy-iodovinylestradiol (radioactive ligand) was used to diagnose 
estrogen receptors in breast carcinogenic cells [73].
5.4 Low density lipoprotein (LDL) receptors
Plasma lipoprotein transports cholesterol towards adrenal gland that act as the 
substrate for synthesis of steroid hormone. 131I-iodomethyl-norcholeterol  
Figure 18. 
Schematic representation of radiotheranostics using radiolabeled peptides [70].
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(NP 59) used to identify patients suffering from adrenal cortex. Cholesterol ana-
logs, 131I-iodocholestrol and 75Se-iodomethyl-norcholestrol, are under investiga-
tion for clinical advantages to detect malignant tissues. Besides N59, various iodine 
labeled hormonal products are undergo transportation and localization with the 
help of LDL receptors. A corticosteroid, Dexamethasone, reduce cholesterol uptake 
by controlling the production of ACTH [74].
6. Conclusion
Accumulation of radiopharmaceuticals at diseased cells through one or variety 
of localization mechanisms describes the specificity and efficacy of the tracer agent. 
The description of different localization mechanisms in above sections, helps in 
developing new radiopharmaceuticals for theranostics. However, the success of 
the radiopharmaceutical depends on the accumulation of radiopharmaceutical at 
specific target cells in term of per cent of injected dose per gram organ or tissue. 
According to the survey of literature, which has been cited in this chapter, different 
localization processes are quite promising but the receptor based localization of 
radiopharmaceuticals is the most successful nuclear medicine procedure both in 
diagnosis and therapeutic treatments of global fatal diseases.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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